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Summary: Lysophospholipids (LPLs) are important interme-
diates in the synthesis and degradation of membrane phospho-
lipids. Here we show that certain LPLs, particularly lysophos-
phatidylcholine and lysophosphatidylinositol, prevent neuronal
death both in an in vivo model of transient global ischemia and
in an in vitro model of excitotoxicity using primary cultures of
cerebellar granule cells exposed to high extracellular concen-
trations of glutamate (20–40 mol/L). The intravenous injec-
tion of lysophosphatidylcholine or lysophosphatidylinositol at a
concentration of 200 nmol/kg induced a survival of CA1 py-
ramidal neurons as high as approximately 95%, even when the
treatment was started 30 minutes after 15-minute global isch-
emia. In contrast, lysophosphatidic acid induced no protection.
This work also provides evidence that a pretreatment with ly-
sophosphatidylcholine or lysophosphatidylinositol (200
nmol/kg) injected as long as 3 days before a severe 6-minute
ischemia provided a potent tolerance against neurodegenera-
tion. Neuroprotection was also observed in in vitro experiments
with LPLs. Taken together, in vivo and in vitro data suggest a
potential therapeutic use of LPLs as antiischemic compounds.
The potential role of 2P-domain K+ channels as targets of LPLs
in this potent neuroprotective effect is discussed. Key Words:
Forebrain ischemia—Excitotoxicity—2P-domain K+ chan-
nels—Lysophospholipids—Ischemic tolerance.
Cerebral ischemia is a major cause of death and long-
term disability, annually affecting more than 700,000
people in the United States alone. During a stroke or
other ischemic event in the brain, the cerebral blood flow
is reduced and the resulting oxygen and glucose depri-
vation rapidly initiates a sequence of events leading to
neuronal cell death. Neurons at risk die as a result of a
neurotoxic biochemical cascade initiated by reduced en-
ergy stores, membrane depolarization, excessive excit-
atory amino acid release, accumulation of free fatty ac-
ids, and elevated intracellular calcium and neuronal
hyperexcitability (Bazan, 1970; Choi and Rothman,
1990; Meldrum, 1995; Siesjö and Wieloch, 1985). While
pharmacologic therapy to reduce ischemic damage is be-
ing pursued, neuroprotective compounds have failed in
clinical trials despite promising preclinical data (Jain,
2000). Growing evidence indicates that the opening of
potassium channels might provide a potent protective
effect against cerebral ischemia/reperfusion injury. For
example, activators of KATP channels have been de-
scribed to prevent neuronal death induced by ischemic,
epileptic, or excitotoxic injuries (Abele and Miller, 1990;
Blondeau et al., 2000; Heurteaux et al., 1993; Lauritzen
et al., 1997).
The recent discovery of a new family of mammalian
two-pore (2P)-domain K+ channels (Lesage and Lazdun-
ski, 2000) has suggested a new strategy for neuroprotec-
tion. These channels are present in the brain at synaptic
and nonsynaptic sites (Hervieu et al., 2001; Lauritzen et
al., 2000; Maingret et al., 2000a; Reyes et al., 2000;
Talley et al., 2001). They have very peculiar functional
properties, and many are background channels with an
important role in the regulation of the resting potential
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(Lesage and Lazdunski, 2000; Patel and Honore, 2001;
Patel et al., 2001). Some 2P-domain K+ channels
(TREK-1, TREK-2, and TRAAK) are mechanosensitive
channels. These same channels are also reversibly
opened by polyunsaturated fatty acids (PUFAs). Since
PUFAs are potent neuroprotectors in brain pathologies
such as global ischemia and epileptic seizures (Lauritzen
et al., 2000; Leaf et al., 1999) and induce ischemic and
epileptic tolerance (Blondeau et al., 2001), it has been
suggested (Blondeau et al., 2001; Lauritzen et al., 2000)
that this effect is largely due to the opening of TREK-1,
TREK-2, and TRAAK channels. Another interesting
property of these particular TREK and TRAAK channels
is that they are potently activated by lysophospholipids
(LPLs) (Lesage et al., 2000; Maingret et al., 2000b).
Lysophospholipids are produced in parallel with PUFAs
by hydrolysis of membrane phospholipids by phospho-
lipases A2 (Dennis, 1997; Valentin and Lambeau, 2000).
Because PUFAs are potent neuroprotectors (Blondeau et
al., 2001), the present work aims to investigate the po-
tential protective effect of LPLs on neuronal death in the
selectively vulnerable regions of rat hippocampus after
transient global cerebral ischemia induced by four-vessel
occlusion. The study also analyzes the effect of LPLs on
the viability of cultured cerebellar granule cells treated
with glutamate in neurotoxic concentrations in vitro.
MATERIALS AND METHODS
Animals
Animal experiments were approved by the local committee
review board and were conducted according to policies on the
care and use of laboratory animals of the Society of Neurosci-
ences. Male Wistar rats weighing 250 to 300 g (Charles River
Breeding Laboratories) were used. The animals, maintained on
a 12/12 hours light/dark cycle, were given food and water ad
libitum and were acclimated to the animal facility for at least 1
week prior to drug treatment or surgery. Anesthesia was in-
duced with 2% halothane mixed with 30% oxygen and 70%
nitrous oxide. Core temperature was monitored continuously
with a thermometer (3-mm probe diameter; Harvard Apparatus,
France) inserted into the rectum and maintained at physiologic
temperatures using a thermostatically controlled heating blan-
ket (Harvard Apparatus, France). Brain temperature was moni-
tored with a temperature monitor (Licox pO2 Monitor, Ger-
many) and, as previously reported (Cao et al., 2001), a 29-
gauge thermocouple implanted 3.5-mm deep into the left
caudate putamen (3.0 mm lateral and 1.40 mm occipital of the
bregma) rather than in the hippocampus to avoid mechanical
hippocampal injury. Core and brain temperatures were main-
tained at physiologic temperatures by a combination of the
homeothermic blanket control unit and adjustment of a tem-
perature regulated-heating lamp, which was placed over the
head of the animal. The femoral artery was catheterized with
polyethylene tubing (PE50) for continuous monitoring of mean
arterial blood pressure (mm Hg) with a blood pressure trans-
ducer (Harvard Apparatus).
Global forebrain ischemia
Global cerebral ischemia lasting 6 or 15 minutes followed by
reperfusion was induced by four-vessel occlusion in anesthe-
tized rats as previously described (Pulsinelli and Brierley,
1979). Animals were placed in a Kopf stereotaxic frame and the
vertebral arteries were irreversibly occluded by electrocoagu-
lation at the junction of the C1 and C2 vertebrae. The common
carotid arteries were then exposed and small-diameter silicon
tubing was looped around the carotid arteries to facilitate sub-
sequent occlusion. On the following day, the animals were
ventilated with 1% halothane and atraumatic miniature aneu-
rysm clips were attached to occlude both common carotid ar-
teries. Anesthesia was then discontinued and carotid arteries
were clamped for 6 or 15 minutes. Rats lost their righting reflex
during ischemia. The EEG was monitored as previously de-
scribed (Lauritzen et al., 2000) to ensure isoelectricity during
the period of ischemia. Negative controls were sham-operated
rats. Vehicle-injected rats treated 30 minutes prior to 15-minute
ischemia or 3 days prior to 6-minute ischemia were used as
positive controls.
Drug treatments
All chemicals were purchased from Avanti Polar Lipids and
Sigma. Stock solutions were kept at −20°C and renewed
weekly. Lysophosphatidylcholine (LPC; C14:0), 1-palmitoyl-
LPC (C16:0), lysophosphatidic acid (LPA; C18:1), and LPI
L--lysophosphatidylinositol) were complexed with an equal
concentration of fatty acid-free bovine serum albumin dis-
solved in Ca2+-free Hanks balanced solution. Stock solutions of
LPLs (10 mol/L) were then diluted in NaCl 0.9% solution to
reach final concentration. The pH of solutions was adjusted to
7. The LPLs were administered by the intraperitoneal route or
injected as a bolus directly in the tail vein at different times
before occlusion of carotid arteries or 30 minutes after the onset
of ischemia. The range of concentrations used in that study was
selected based on optimal neuroprotection results obtained
from a previously obtained dose-response profile with PUFAs
(Lauritzen et al., 2000).
Quantification of neuronal loss on cresyl
violet-stained sections
Seven days after exposure to global ischemia, animals were
deeply anesthetized and decapitated. Brains were quickly ex-
tracted and fresh frozen in isopentane at −40°C. Sections (10
m) were cut on cryostat (Leica) and postfixed by immersion
in 4% paraformaldehyde/10−2 mol/L phosphate-buffered saline
(PBS) for 30 minutes. Slides were then dehydrated in ethanol
baths (50%, 70%, and 100%), air dried, and stored at −70°C
until further use. For each brain studied (n  6 per time point
and condition), two sections were placed on 3-aminopropyl-
ethoxysilane–coated slides, and 10 slides (randomly chosen)
per rat were used in each stage of analysis. A neuropathologist
who was blinded to the experimental conditions performed the
histologic assessment using light microscopy. The neuronal
density of hippocampal CA1 and CA3 subfields was deter-
mined by the method of Kirino (1982). Analysis of neuronal
density was performed on coronal sections of the dorsal hip-
pocampus stained with cresyl violet and corresponding to brain
sections located between 3.14 and 4.16 mm posterior to bregma
(Paxinos and Watson, 1986). The total linear length of CA1 and
CA3 sectors was measured by means of a digitizer. The number
of living neurons in the stratum pyramidale within CA1 and
CA3 subfields was counted using a Leica Aristoplan photomi-
croscope at a magnification of 400×. The neuronal density of
CA1 and CA3 sectors (i.e., the number of intact pyramidal cells
per 1-mm linear length of the CA1/CA3 stratum pyramidale
observed in each 10-m section) was quantified. Thus, a mean
value for each hippocampal CA1/CA3 substructure was ob-
tained from 10 bilateral measurements on two sections per slide
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and 10 slides per rat, for the six animals in each of experimental
groups. Measurements obtained from the 20 sections for a
given animal were averaged to yield a single value of the
CA1/CA3 neuronal density, which was then used in the statis-
tical analysis. Results are reported as mean ± SD. The signifi-
cance of differences between means was assessed by two-factor
analysis of variance followed by the Tukey test for multiple
comparisons, where P < 0.05 was considered statistically
significant.
Isolation of hippocampal proteins and heat-shock
protein 70 Western blotting
Rat hippocampi (n  3 per experimental group) were ho-
mogenized in four volumes of lysis buffer (20 mmol/L Tris pH
7.5, 137 mmol/L NaCl, 2 mmol/L EDTA, 1% Triton ×100,
10% glycerol, and protease-inhibitor cocktail) on ice using a
Dounce homogenizer. After being removed from ice and ex-
posed to room temperature for 10 minutes, the homogenates
were centrifuged at 12,000 g for 30 minutes at 4°C. The su-
pernatant was stored at −70°C until further use. Protein con-
centrations were measured using conventional Bradford’s
method.
Expression of heat-shock protein 70 (HSP70) in hippocampi
following LPI injection was determined using immunoblotting
analysis. Aliquots containing 50 g proteins were applied to
10% SDS PAGE gels and electrophoresed for 1 hour at 100
mA. Proteins were transferred onto nitrocellulose membrane
(Hybond-C) in blotting buffer (156 mmol/L Tris, 1 mol/L gly-
cine, PBS) for 90 minutes at 80 mA and blocked with 5% skim
milk (Regilait) in PBS for 2 hours at room temperature. The
blotted membrane was incubated with the mouse monoclonal
HSP70 antibody (BD Transduction Laboratories, diluted
1/1000) for 2 hours at room temperature. After washing with
0.1% TWEEN/PBS (four times, 15 minutes each), peroxidase-
conjugated goat antimouse IgG antibody was used as the sec-
ond antibody (Jackson ImmunoResearch, diluted 1/15000) for
1 hour at room temperature.
Fluorography was performed on Kodak-X-OMAT AR film
using Western blotting detection reagents (Pierce) following
conventional enhanced-chemiluminescence technique. To con-
trol for sample loading, the membranes containing the original
antibody were stripped and rehybridized with a -tubulin an-
tibody as internal control (data not shown). The specific bands
obtained with both antibodies were quantified by densitometry
using an imaging analysis system.
L-Lyso-3-phosphatidylcholine,1-[1–14C] palmitoyl
transport across the blood–brain barrier
Intravenous L-Lyso-3-phosphatidylcholine,1-[1–14C]
palmitoyl injection technique. The transport of LPLs through
the rat blood–brain barrier was determined by using radioactive
of L-Lyso-3-phosphatidylcholine,1-[1–14C] palmitoyl and by
measuring the uptake of this labeled compound into the brain
after short in situ tail-vein perfusion. The in situ brain perfusion
technique of Takasato et al. (1984) was used, except that the
perfusion was in the tail vein, similar to the different treatments
administrated in that study, and 1 mg/mL (14 mol/L) fatty
acid-free bovine serum albumin and no Ca2+ ions were in-
cluded in bicarbonate-based salt solution (HBSS). The pH-7.4
medium containing 142.0 mol/mL NaCl, 28.0 mol/mL
NaHCO3, 4.2 mol/mL KH2PO4, 1.0 mol/mL MgSO4, and 6
mol/mL glucose was equilibrated with a gas mixture of 95%
oxygen and 5% carbon dioxide at 37°C for 5 minutes. Radio-
active L-Lyso-3-phosphatidylcholine,1-[1–14C] palmitoyl was
dissolved in HBSS to give a 20 mol/L concentration in the
perfusate, with a specific radioactivity of 56 mCi/mmol (Am-
ersham Pharmacia Biotech, France). Unlabeled L-Lyso-3-
phosphatidylcholine,1-palmitoyl (final concentration, 1
mmol/L) was also added in the perfusion medium. The tail vein
of rats anesthetized with a flow of O2/N2O gas mixture con-
taining 1% halothane was cannulated with a 24-gauge catheter
(Vitaflon Plus, Ohmeda, Becton Dickinson, France). At time
zero, halothane was discontinued and the injection of the per-
fusate was begun at a constant rate of 83 L/sec by a perfusion
pump for 15 seconds and continued with HBSS solution for
periods of up to 20 seconds. At the end of the perfusion, the
brain was removed from the skull and rinsed in ice-cold saline.
The meninges and blood vessels on the surface of the brain
were carefully removed.
Lipid extraction. Lipids were extracted from the brain with
a mixture of chloroform, methanol, and water (50:25:25 by
volume) and then two times with chloroform and methanol (2:1
volume:volume). The lipid extract was concentrated by evapo-
rating the solvent under a stream of nitrogen and dissolved in 1
mL chloroform/methanol (2:1 volume:volume) to be parti-
tioned according to the standard procedure of Folch et al.
(1957). The washed organic phases were concentrated and the
dissolved radioactive lipids were resolved by monodimensional
TLC on activated silica gel 60-coated plates (20 × 20 cm, 0.20
mm thickness; Merck Eurolab, France), using a mixture of
chloroform, methanol, and NH4OH (65:30:5 by volume) to
develop the plates. Lipids, which were revealed by resublimed
iodine, were identified using Rf values relative to authentic
standards. The identified areas of silica gel were scraped off
and eluted with chloroform and methanol (1:1 volume:volume).
Aliquots of solution containing each individual or combined
class of brain phospholipids were transferred to plastic vials,
dried, dissolved in scintillation cocktail fluid (Ecolume, ICN),
and measured for 14C radioactivity (Packard scintillation
counter model 1600 CA).
Cerebellar granule cell culture
Cerebellar granule cells were prepared from 6- or 7-day-old
OF1 mice (Iffa Credo, France) as previously described
(Schousboe et al., 1989). Neurons were seeded on poly-L-
lysine (50 g/mL)-coated dishes at a density of 2.6 × 106 cells
per 35-mm culture dish and cultured in Eagle basal medium
(Sigma) supplemented with 10% fetal calf serum (Gibco), 25
mmol/L KCl, and 0.5% penicillin-streptomycin. To prevent
growth of glial cells, cytosine arabinoside (10 mol/L) was
added to the cultures 24 hours following plating. Unless oth-
erwise stated, experiments were performed using 8- or 9-day-
old cultures.
In vitro model of excitotoxicity
Glutamate treatment was performed in magnesium-free gly-
cine-supplemented PBS. Control cells were exposed to the
same buffer without glutamate. Lysophospholipids (LPC
[C14:0], LPA [C18:1], and LPI [L--lysophosphatidylinositol];
10 mol/L) were added as stated either 15 minutes before and
during, or during and after the treatment with glutamate. Con-
trol cells were incubated with vehicle alone. Unless otherwise
stated, cell viability was estimated 6 hours after treatment.
Assessment of cell viability
Neuronal injury was quantitatively assessed by the measure-
ments of lactic dehydrogenase (LDH) in the medium (Koh and
Choi, 1987). Lactic dehydrogenase activities, measured at
OD340, were expressed as activity present in the total medium
volume/total LDH activity (media + cells) and are presented as
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release of LDH as a percentage of that in glutamate-treated
cells.
Cell death was determined using a fluorescent chromatin-
fixing dye propidium iodide (PI) staining procedure. Cells were
fixed with freshly prepared paraformaldehyde 4%, and left in
70% ethanol overnight. Cells were incubated in PBS containing
PI (5 g/mL) for 10 minutes. The nuclei of dead cells were
highly fluorescent and condensed compared with living cells.
Dead cells were scored by counting at least 600 cells in several
randomized subfields for each sample from three different ex-
periments. The percentage of LDH activities or of PI-pyknotic
nuclei was used for statistical analysis by ANOVA followed by
a Fischer PLSD for multiple comparisons (P < 0.05).
RESULTS
Lysophospholipids protect against
glutamate-induced cell death in cerebellar
granular cultures
First, we examined the effects of LPLs on glutamate-
induced cell death in primary cultures of cerebellar
granular neurons. Cell death was estimated by measuring
cell leakage and nuclei condensation. When the granule
cells were exposed to 20 mol/L glutamate, no signs of
cell death were observed in the first hours after the ex-
posure, though cells died during the next several hours
(Figs. 1A, left, and 1B). Cell leakage, measured by the
release of LDH, remained relatively low (Fig. 1A, left),
but the treatment led to the appearance of a high number
of pyknotic nuclei, which may be explained by the pres-
ence of both necrotic and apoptotic neurons (Ankarcrona
et al., 1995; Bachis et al., 2001; Lauritzen et al., 2000).
We analyzed the effect of the lysophospholipid LPC on
this glutamate-induced cell death. First, we wanted to
establish the optimal concentration of LPC. Since it is
well known that lysophospholipids from Avanti Polar
Lipids are very pure and do not contain any contaminat-
ing lipids, as suspected in those obtained from Sigma
(Liliom et al., 1998), we used LPC from Aventi Polar
Lipids to establish the optimal concentration of the ly-
sophospholipid to be used throughout all other in vitro
experiments. Cells were exposed to 20 mol/L glutamate
in the presence of different concentrations of LPC
(C14:0; 1, 5, 10, and 20 mol/L) (Fig. 1A, left). Maxi-
mal protection was obtained at a concentration of 10
mol/L, and the corresponding Sigma product, at an
identical concentration, produced a similar protection
(Fig. 1A, left). At a lower concentration (1 mol/L),
LPC was not able to prevent cell death, and a higher
concentration (20 mol/L) did not produce a protection
better than that found with 10-mol/L concentration.
Since the LPC obtained from Sigma caused the same
neuroprotective effect as LPC from Aventi, we used
Sigma LPLs at a concentration of 10 mol/L throughout
all other experiments.
The cells were then exposed to a higher concentration
of 40 mol/L glutamate for 15 minutes, which led to cell
FIG. 1. Lysophosphatidylcholine
(LPC)-induced neuroprotection in glu-
tamate-treated granular cell cultures.
(A, left) Granular cells were exposed
to glutamate (20 µmol/L) in the pres-
ence of distinct concentrations of LPC
(C14:0, Aventi Polar Lipids) or 10
µmol/L LPC (C14:0, Sigma). The LPC
was present during (d) and after (a)
the glutamate treatment. (A, right)
Granular cells were exposed to gluta-
mate (40 µmol/L) in the presence of
10-µmol/L LPC (C14:0, Sigma). The
LPC was present either during (d)
and after (a), or before (b), during (d),
and after (a) glutamate treatment.
Cell viability was estimated 6 hours
after treatment by propidium iodide
(PI) staining or lactic dehydrogenase
(LDH)-efflux measurements. The
LDH-efflux was expressed as the per-
centage of efflux of the maximal ef-
flux, which was determined by the
exposure of cells to 1 mmol/L gluta-
mate. (B) Effects of 10-µmol/L LPC
(C14:0, Sigma) on cell death induced
by low (20 µmol/L) or high (40 µmol/L)
concentrations of glutamate. Photo-
micrographs correspond to represen-
tative experiments of PI staining.
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swelling and cell death in the first hours after treatment
(Figs. 1A, right, and 1B). At 6 hours after treatment, the
LDH activity in 40 mol/L glutamate-treated cells was
almost twice the activity of 20 mol/L glutamate-treated
cells, but the numbers of pyknotic nuclei were almost
identical in the two cases (Figs. 1A and 1B). In 40
mol/L glutamate-treated cells, the presence of LPC (10
mol/L) only during and after the glutamate exposure
did not prevent cell death (Figs. 1A, right, and 1B). How-
ever, if cells were preincubated with LPC (10 mol/L)
for 15 minutes before the toxic insult, the appearance of
pyknotic nuclei and LDH activity were significantly re-
duced (Figs. 1A, right, and 1B).
Next, we analyzed the effect of other LPLs on exci-
totoxicity. We used LPI, another lysophospholipid that
activates 2P-domain K+ channels, and LPA, which has
no action on these K+ channels (Maingret et al., 2000b).
Neither LPI nor LPA (10 mol/L) affected cell viability
in normal conditions. When cells were exposed to glu-
tamate (20 mol/L), LPI completely protected against
cell death, whereas LPA had no beneficial effects (Fig.
2). These findings were confirmed using both PI staining
and LDH-efflux measurements.
Physiologic parameters before, during, and after
transient global forebrain ischemia
Mean arterial blood pressure and core and brain tem-
peratures measured at 15 minutes before the induction of
ischemia, 5 minutes after the induction of ischemia, and
at the end of 15-minute ischemia are given in Table 1.
Before the induction of ischemia, mean arterial blood
pressure was maintained close to 76 to 82 mm Hg, re-
duced to 30 to 33 mm Hg during ischemia, and progres-
sively returned to preischemic baseline values during
reperfusion. There were no significant differences among
the groups (Table 1) The average core and brain tem-
peratures were maintained at 36.9°C to 37.5°C before
ischemia. During the ischemic interval, brain and core
temperatures were continually maintained within the
physiologic range, and the temperature stability of the
animals in the different groups was preserved throughout
the reperfusion period. Table 1 shows no significant dif-
ferences among the groups (P < 0.05)
Pretreatment with lysophosphatidylcholine or
lysophosphatidylinositol, but not with
lysophosphatidic acid, prevents hippocampal
neuronal cell death induced by transient global
forebrain ischemia
We analyzed the potential neuroprotective effect of
different LPLs injected shortly before a severe ischemic
insult. Intravenous injection of 200 nmol/kg LPC or
LPI30 minutes before the onset of ischemia almost com-
pletely inhibited neuronal loss, and 97% and 86% of
CA1 pyramidal cells were respectively preserved (Fig.
3A). In contrast, intravenous administration of LPA
failed to protect the brain. When animals were treated
with 200 nmol/kg LPA 30 minutes before ischemia, neu-
ronal counts in CA1 and CA3 pyramidal layers were not
significantly different from counts obtained after isch-
emia (vehicle-injected group) alone; 79% of CA1 neu-
ronal loss was observed in LPA-treated rats (Fig. 3A).
Figure 3B shows the most representative effects of
LPL pretreatment on morphologic changes observed in
the CA1 pyramidal cell layer following severe ischemia.
It confirms the quantitative analysis of neuronal density
for the different experimental conditions. Similar to the
vehicle-injected group, LPA-treated rats exhibited severe
FIG. 2. Effects of distinct lysophos-
pholipids (LPLs) on glutamate-
induced cell death. Granular cells
were exposed to glutamate (20
µmol/L for 15 minutes) in the absence
or presence of distinct LPLs: lyso-
phosphatidylcholine (LPC; C14:0),
and lysophosphatidylinositol (LPI)
and lysophosphatidic acid (LPA;
Sigma, each at 10 µmol/L). Cell death
was estimated 6 hours after treatment
using propidium iodide (PI) staining
and lactic dehydrogenase (LDH)-
efflux measurements. Viability is ex-
pressed as percentage of pyknotic
nuclei for PI staining, and as percent-
age of LDH efflux of the efflux in glu-
tamate-treated cells for LDH-efflux
measurements. Photomicrographs
correspond to representative experi-
ments of PI staining.
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TABLE 1. Mean arterial blood pressure and core and brain temperatures measured at 15 minutes before, and 5 minutes after,
induction of ischemia, and after 15 minutes’ ischemia
Groups Parameters
Preischemia
15 min
Ischemia Reperfusion
5 min 15 min 30 min 60 min
Vehicle Core T° 37.5 ± 0.2 37.4 ± 0.2 37.0 ± 0.3 37.4 ± 0.2 37.6 ± 0.1
Brain T° 37.3 ± 0.1 37.1 ± 0.1 36.9 ± 0.2 37.1 ± 0.3 37.2 ± 0.2
MABP 78.5 ± 3.4 34.6 ± 0.8 33.8 ± 0.9 76.5 ± 3.5 79.5 ± 2.9
I15–LPC (nmol/kg)
200, ip Core T° 37.4 ± 0.3 37.2 ± 0.3 36.9 ± 0.2 37.2 ± 0.3 37.7 ± 0.3
Brain T° 37.1 ± 0.2 36.9 ± 0.2 37.0 ± 0.3 36.9 ± 0.2 37.3 ± 0.2
MABP 80.3 ± 3.6 33.5 ± 1.4 32.7 ± 0.9 73.5 ± 2.8 79.5 ± 3.1
500, ip Core T° 37.2 ± 0.3 37.0 ± 0.1 36.8 ± 0.2 37.1 ± 0.2 37.3 ± 0.2
Brain T° 37.0 ± 0.2 36.4 ± 0.3 36.2 ± 0.3 36.7 ± 0.1 37.2 ± 0.1
MABP 77.2 ± 2.9 31.4 ± 0.9 30.2 ± 1.2 74.8 ± 2.4 79.1 ± 3.2
50, iv Core T° 37.5 ± 0.2 37.4 ± 0.2 37.0 ± 0.3 37.4 ± 0.2 37.6 ± 0.1
Brain T° 37.1 ± 0.2 37.1 ± 0.2 36.8 ± 0.3 36.9 ± 0.2 37.2 ± 0.1
MABP 79.5 ± 3.2 33.8 ± 0.9 32.4 ± 1.1 75.8 ± 2.9 76.6 ± 2.1
100, iv Core T° 37.4 ± 0.3 37.2 ± 0.3 36.9 ± 0.2 37.2 ± 0.3 37.5 ± 0.3
Brain T° 37.0 ± 0.2 36.6 ± 0.2 36.5 ± 0.3 36.9 ± 0.2 37.1 ± 0.2
MABP 81.3 ± 3.6 34.5 ± 1.4 32.7 ± 0.9 75.5 ± 2.8 79.5 ± 3.2
200, iv Core T° 37.5 ± 0.2 37.3 ± 0.2 37.2 ± 0.3 37.6 ± 0.2 37.6 ± 0.1
Brain T° 37.1 ± 0.2 36.7 ± 0.2 36.6 ± 0.3 36.9 ± 0.2 37.2 ± 0.1
MABP 78.5 ± 3.2 31.8 ± 0.9 31.4 ± 1.1 75.8 ± 2.9 76.9 ± 2.1
500, iv Core T° 37.1 ± 0.3 37.1 ± 0.2 36.9 ± 0.3 36.9 ± 0.2 37.4 ± 0.2
Brain T° 37.1 ± 0.2 36.9 ± 0.2 36.5 ± 0.3 36.9 ± 0.2 37.2 ± 0.1
MABP 78.8 ± 3.4 33.6 ± 0.8 32.8 ± 0.9 76.5 ± 3.4 79.5 ± 2.7
I15–LPI (nmol/kg)
50, iv Core T° 37.2 ± 0.3 37.0 ± 0.1 36.8 ± 0.2 37.1 ± 0.2 37.3 ± 0.2
Brain T° 37.1 ± 0.2 36.5 ± 0.3 36.3 ± 0.3 36.7 ± 0.1 37.0 ± 0.1
MABP 79.2 ± 2.9 32.4 ± 0.9 30.8 ± 1.2 72.8 ± 2.4 80.1 ± 3.2
100, iv Core T° 37.5 ± 0.3 37.2 ± 0.1 36.8 ± 0.2 37.1 ± 0.2 37.4 ± 0.3
Brain T° 36.9 ± 0.2 36.8 ± 0.2 36.5 ± 0.3 36.7 ± 0.1 37.1 ± 0.2
MABP 78.7 ± 2.9 32.9 ± 1.2 31.2 ± 1.4 75.8 ± 2.4 79.7 ± 3.4
200, iv Core T° 37.3 ± 0.2 36.9 ± 0.3 36.4 ± 0.2 36.7 ± 0.3 37.2 ± 0.3
Brain T° 37.1 ± 0.3 36.6 ± 0.3 36.6 ± 0.2 37.0 ± 0.2 37.3 ± 0.2
MABP 79.3 ± 2.9 33.8 ± 2.3 32.9 ± 0.7 73.7 ± 3.1 79.9 ± 3.7
I15–LPA (nmol/kg)
50, iv Core T° 37.5 ± 0.2 37.0 ± 0.1 36.5 ± 0.2 37.3 ± 0.2 37.8 ± 0.2
Brain T° 37.2 ± 0.2 36.9 ± 0.2 36.8 ± 0.2 36.9 ± 0.2 37.3 ± 0.1
MABP 77.9 ± 3.7 30.8 ± 1.1 31.4 ± 1.1 76.2 ± 2.7 76.8 ± 2.4
100, iv Core T° 37.3 ± 0.2 37.2 ± 0.2 37.0 ± 0.3 37.5 ± 0.2 37.6 ± 0.1
Brain T° 37.1 ± 0.1 37.1 ± 0.1 36.9 ± 0.2 37.1 ± 0.3 37.2 ± 0.2
MABP 82.5 ± 3.7 37.6 ± 0.6 35.8 ± 0.9 78.5 ± 3.7 81.5 ± 2.7
200, iv Core T° 37.6 ± 3.7 37.5 ± 0.3 37.3 ± 0.2 37.4 ± 0.3 37.5 ± 0.2
Brain T° 37.1 ± 0.2 36.3 ± 0.4 36.1 ± 0.3 36.9 ± 0.2 36.9 ± 0.3
MABP 76.3 ± 3.9 33.5 ± 1.7 32.9 ± 0.8 75.8 ± 2.8 77.5 ± 3.5
500, iv Core T° 37.5 ± 0.1 37.2 ± 0.1 36.3 ± 0.2 37.1 ± 0.2 37.7 ± 0.3
Brain T° 37.0 ± 0.2 36.5 ± 0.2 36.4 ± 0.3 36.9 ± 0.2 37.1 ± 0.1
MABP 75.9 ± 3.9 31.4 ± 1.4 30.8 ± 1.1 76.4 ± 2.2 77.4 ± 2.6
30 min–I15 (nmol/kg)
LPA Core T° 37.7 ± 0.4 37.2 ± 0.2 36.7 ± 0.2 37.0 ± 0.3 37.1 ± 0.1
Brain T° 36.9 ± 0.1 36.4 ± 0.2 36.5 ± 0.4 37.1 ± 0.2 37.2 ± 0.3
MABP 82.7 ± 3.8 36.6 ± 1.8 33.7 ± 0.7 76.9 ± 2.8 78.6 ± 3.4
LPI Core T° 37.2 ± 0.4 37.1 ± 0.2 36.9 ± 0.3 37.2 ± 0.2 37.7 ± 0.4
Brain T° 37.1 ± 0.2 36.9 ± 0.2 36.5 ± 0.3 36.9 ± 0.2 37.1 ± 0.1
MABP 80.5 ± 3.4 37.8 ± 0.8 31.6 ± 1.4 71.8 ± 2.9 79.6 ± 2.4
LPC Core T° 37.3 ± 0.3 37.1 ± 0.2 36.5 ± 0.3 37.4 ± 0.2 37.5 ± 0.2
Brain T° 37.0 ± 0.2 36.7 ± 0.4 36.2 ± 0.3 36.9 ± 0.3 37.1 ± 0.2
MABP 77.4 ± 3.5 37.9 ± 0.7 31.7 ± 1.1 76.9 ± 3.5 79.4 ± 2.5
3 days–I6 (nmol/kg)
LPI Core T° 37.3 ± 0.2 37.0 ± 0.2 – 37.1 ± 0.2 37.2 ± 0.3
Brain T° 36.9 ± 0.3 36.6 ± 0.2 – 36.6 ± 0.3 37.0 ± 0.2
MABP 79.6 ± 3.6 37.6 ± 0.9 – 77.5 ± 3.2 77.6 ± 2.8
LPC Core T° 37.1 ± 0.2 37.0 ± 0.2 – 37.2 ± 0.2 37.1 ± 0.3
Brain T° 36.8 ± 0.2 36.6 ± 0.3 – 36.6 ± 0.3 37.0 ± 0.1
MABP 81.5 ± 3.9 39.6 ± 0.8 – 73.4 ± 3.1 83.6 ± 0.9
I6 and I15, 6-minute and 15-minute global ischemia, respectively; LPC, lysophosphatidylcholine; LPI, lysophosphatidylinositol; LPA, lysophos-
phatidic acid; ip, intraperitoneally; iv, intravenously.
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damage of pyramidal neurons indicated by pyknotic
nuclei and an irregular shape. In contrast, LPC- and
LPI-treated animals displayed many healthy CA1 neu-
rons indicated by their round soma and distinct nuclei
(Fig. 3B).
Posttreatment with lysophosphatidylcholine or
lysophosphatidylinositol, but not with
lysophosphatidic acid, prevents hippocampal
neuronal cell death induced by transient global
forebrain ischemia
The efficiency of posttreatment with LPLs against
ischemia-induced neuronal damage has been tested in
relation to the type of injection (intraperitoneal vs. intra-
venous) and the dose used. Figures 4 and 5 summarize
the scores of quantified neuronal damage in hippocampal
cell layers of ischemic, LPC-treated (Fig. 4), LPI-treated,
and LPA-treated rats (Fig. 5). Figure 6 presents the most
representative histopathological examples obtained for
the corresponding experimental conditions. As previ-
ously observed (Lauritzen et al., 2000; Schmidt-Kastner
and Freund, 1991), complete forebrain ischemia for 15
minutes induced significant neuronal cell death in the
CA1 subfield and, to a lesser extent, in the CA3 pyra-
midal layer. Compared with the sham-operated group,
85% and 43% of CA1 and CA3 pyramidal cell popula-
tions showed signs of neuronal damage in the ischemic
group, respectively (Figs. 4 and 6). Intraperitoneal injec-
tion of 200-nmol/kg or 500-nmol/kg LPC 30 minutes
after the end of global ischemia did not induce neuronal
protection. The neuronal density in CA1 and CA3 pyra-
midal layers of both LPC-treated groups was not signifi-
cantly different from that of the ischemic vehicle-
injected group (which showed an approximate 80%
neuronal loss in the CA1 field; Figs. 4 and 6). When
animals were given LPC intravenously 30 minutes after
the end of ischemia, there was a dose-dependent increase
FIG. 3. Effects of different lysophos-
pholipids (LPLs; lysophosphatidyl-
choline [LPC], lysophosphatidylinosi-
tol [LPI], and lysophosphatidic acid
[LPA]), injected 30 minutes before 15-
minute ischemia, on neuronal sur-
vival. (A) Neuronal densities of CA1
and CA3 of rats injected with LPC,
LPI, and LPA 30 minutes prior to isch-
emia. Histograms represent the neu-
ronal density assessed in cresyl vio-
let-stained sections per 1-mm linear
length of hippocampal CA1 and CA3
pyramidal layers in the different ex-
perimental groups subjected to 15-
minute global ischemia. Data repre-
sent the mean values ± SEM of
counts from two brain sections per
slide and 10 slides per rat (n = 6 per
group). (B) Representative photomi-
crographs highlighting the effects of
pretreatment with LPC, LPI, and LPA
on morphologic changes at the CA1
pyramidal cell layer assessed using
cresyl violet staining in rats killed 7
days following ischemia. The LPA,
LPI, and LPC were intravenously in-
jected at a dose of 200 nmol/kg 30
minutes before 15-minute ischemia.
LPC corresponds to LPC (C14:0) ad-
ministration at a dose of 200 nmol/kg.
Sham corresponds to sham-operated
rats injected with vehicle and vehicle
to ischemic rats injected with vehicle
30 minutes days before the onset of
15 minutes ischemia. Differences
were considered statistically signifi-
cant when P < 0.05 (Tukey test). *Sig-
nificantly different from ischemic ani-
mals, #significantly different from
sham-operated animals.
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in neuronal survival that reached maximal levels (94% of
sham-operated CA1 controls) at 200 nmol/kg. At higher
dose (500 nmol/kg), neuronal survival declined (Figs. 4
and 6). Compared with the sham-operated group, intra-
peritoneal or intravenous injection of 500-nmol/kg LPC
alone did not change neuronal counts (Figs. 4 and 6).
Treatment with doses of LPI ranging from 50 to 200
nmol/kg given intravenously after the onset of ischemia
induced a potent neuronal protection. The three doses
FIG. 5. Quantitative analysis of CA1 and CA3 cell survival ob-
tained with different lysophospholipids (LPLs; lysophosphatidyli-
nositol [LPI] and lysophosphatidic acid [LPA]) injected 30 minutes
after the end of the ischemic period. Histograms represent the
neuronal density assessed in cresyl violet-stained sections per
1-mm linear length of hippocampal CA1 and CA3 pyramidal lay-
ers in the different experimental groups submitted to 15-minute
global ischemia. Data represent the mean values ± SEM from
counts of two brain sections per slide and 10 slides per rat (n = 6
per group). LPI50, LPI100, and LPI200 correspond to LPI admin-
istration at a dose ranging from 50 to 200 nmol/kg. LPA50,
LPA100, LPA200, and LPA500 correspond to LPA administration
at a dose ranging from 50 to 500 nmol/kg. All LPLs were intra-
venously injected. Sham corresponds to sham-operated rats in-
travenously injected with vehicle and vehicle to rats subjected to
15-minute global ischemia and intravenously injected with vehicle
30 minutes after the end of the ischemic period. Differences were
considered statistically significant when P < 0.05 (Tukey test).
*Significantly different from ischemic animals, #significantly dif-
ferent from sham-operated animals.
FIG. 4. Quantitative analysis of CA1 and CA3 cell survival ob-
tained with different concentrations of lysophosphatidylcholine
(LPC) injected 30 minutes after 15-minute global ischemia. His-
tograms represent the neuronal density assessed in cresyl violet-
stained sections per 1-mm linear length of hippocampal CA1 and
CA3 pyramidal layers in the different experimental groups sub-
jected to 15 minutes global ischemia. Data represent the mean
values ± SEM from counts of two brain sections per slide and 10
slides per rat (n = 6 per group). LPC50, LPC100, LPC200 and
LPC500 correspond to LPC (C14:0) administration at a dose
ranging from 50 to 500 nmol/kg injected intraperitoneally or in-
travenously 30 minutes after 15-minute global ischemia. Sham
corresponds to sham-operated rats injected with vehicle and ve-
hicle to rats subjected to 15-minute global ischemia and injected
with vehicle 30 minutes after the end of the ischemic period.
Differences were considered statistically significant when P <
0.05 (Tukey test). *Significantly different from vehicle-injected
ischemic animals, #significantly different from sham-operated
animals.
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tested (50, 100, and 200 nmol/kg) limited the CA1 and
CA3 cell destruction to approximately 7% and 11% of
neurons (Figs. 5 and 6). In contrast, intravenous injec-
tions of different doses of LPA (50–500 nmol/kg) had no
beneficial effect on neuronal cell death (Fig. 6). Neuro-
nal counts in CA1 and CA3 pyramidal layers were not
significantly different from counts obtained after isch-
emia (vehicle-injected group). Approximately 82% and
40% of neuronal loss in CA1 and CA3 was observed,
respectively (Fig. 5). For control, a single injection of
500-nmol/kg LPA did not affect the neuronal counts. The
average neuronal density in pyramidal cell layers of
LPC- and LPI-treated rats was not significantly different
from that of the sham-operated group (Figs. 5 and 6).
Lysophospholipids induce ischemic tolerance
against transient global forebrain ischemia
To test the hypothesis that the LPLs described previ-
ously as potent neuroprotectors may induce a brain tol-
erance when injected days before the ischemic event, rats
were intravenously injected with 200-nmol/kg LPC or
LPI at different times prior to 6-minutes global ischemia,
the pharmacologic preconditioning induced neuroprotec-
tion depending on the latency between treatment and
ischemic insult. As previously described (Blondeau et
al., 2000; Blondeau et al., 2001; Heurteaux et al., 1995;
Smith et al., 1984), 6-minute ischemia produced severe
neuronal damage. Only 21% and 63% of CA1 and CA3
pyramidal cells were preserved, respectively (Fig. 7). In-
jection of 200-nmol/kg LPC or LPI injected 24, 48, or 72
hours before 6-minute ischemia almost completely in-
hibited this neuronal loss. The average neuronal densities
in pyramidal cell layers of LPC-treated and LPI-treated
rats were not significantly different from that of the
sham-operated group (Fig. 7). However, when LPC or
LPI (200 nmol/kg) was injected as early 6 hours or as
long 4 days before 6-minute ischemia, CA1 and CA3
pyramidal cell layers were strongly damaged and showed
neuronal densities comparable with the vehicle-injected
ischemic group (Fig. 7). The morphologic changes ob-
served in the CA1 pyramidal cell layer 7 days following
severe ischemia in rats pretreated with LPC at different
times before ischemia are shown in Fig. 8A and confirm
the temporal window of effective pretreatment (1–3
days). Similar morphologic changes were observed in
CA1 substructure of rats pretreated with LPI (data not
shown).
Several lines of evidence indicate that the develop-
ment of cerebral tolerance in vivo coincides with the
induction of expression of the 70-kDa HSP70 within the
time window of protection (Blondeau et al., 2000;
Blondeau et al., 2001; Kirino et al., 1991). To confirm
the establishment of a pharmacologic preconditioning by
a pretreatment with LPLs, the current study investigated
the potential temporal profile of HSP70 synthesis in hip-
pocampus following pretreatment with LPLs at different
times before ischemia. Figure 8B depicts the induction of
HSP70 protein in the hippocampus at 6, 24, 48, 72, and
96 hours following LPI treatment assessed using West-
ern blot analysis. HSP70 protein remained weakly de-
tectable in protein extracts from hippocampi of rats in-
jected with vehicle at any time following injection or
with 200-nmol/kg LPI at 6 hours after injection. The
administration of 200-nmol/kg LPI led to a progressive
accumulation of HSP70 protein detected in hippocampi
24 hours following LPI treatment with a maximal ex-
pression level reached at 72 hours.
Analysis of 1-palmitoyl-lysophosphatidylcholine
transport across the blood–brain barrier
To evaluate how much and what form of LPL is en-
tering the brain, 1-[1–14C]-palmitoyl-LPC was intrave-
nously injected according to the protocol of Alberghina
et al. (1994). Figure 9A shows the percent distribution of
radioactivity of total lipids extracted from brain, liver,
spleen, and kidney after short-time tail-vein injection.
When the perfusions were carried out for 15 seconds,
approximately 0.10% of the perfused 1-[1–14C]-
palmitoyl-LPC was entering into the brain. The radioac-
tivity distribution among metabolic products in the or-
ganic phase of brain lipid extracts was as follows:
unmetabolized LPC (55%), phosphatidylcholine (30%),
and saturated fatty acid palmitate (15%). Figure 9B
FIG. 6. Representative photomicrographs highlighting the ef-
fects of different LPLs (lysophosphatidylcholine [LPC], lysophos-
phatidylinositol [LPI], and lysophosphatidic acid [LPA]) injected
30 minutes following the end of the ischemic period on morpho-
logic changes at the CA1 pyramidal cell layer assessed using
cresyl violet staining in rats killed 7 days following ischemia. The
LPLs were injected intravenously. LPC200 corresponds to LPC
(C14:0) administration at a dose of 200 nmol/kg. LPI200,
LPA200, LPC200, and LPC500 correspond to LPI, LPA, or LPC
treatment at a dose ranging from 200 to 500 nmol/kg. Sham
corresponds to sham-operated rats intravenously injected with
vehicle and vehicle to rats submitted to 15-minute global isch-
emia and intravenously injected with vehicle 30 minutes after the
end of ischemia. Scale bar = 100 µm.
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shows that a treatment with 1-palmitoyl-LPC prevented
hippocampal neuronal death induced by transient (15-
minute) global ischemia. An injection of 200-nmol/kg
1-palmitoyl-LPC given intravenously 30 minutes before
15-minute ischemia (data not shown) or 30 minutes after
the onset of 15-minute ischemia (Fig. 9B) induced a
potent neuronal protection. Compared with the vehicle-
injected rats, where CA1 and CA3 pyramidal cell layers
showed severe signs of neuronal damage, the 1-palmi-
toyl-LPC–treated animals were strongly protected
against ischemia. The findings that phosphatidylcholine
does not activate TREK and TRAAK channels (Maingret
et al., 2000b), saturated fatty acid palmitate does not
protect against global ischemia (Lauritzen et al., 2000;
Maingret et al., 2000b), and 1-palmitoyl-LPC treatment
provides a potent neuroprotection against ischemic insult
strongly suggest that the unmetabolized LPL fraction
(55% LPC in that case) is responsible of neuroprotective
effects.
DISCUSSION
Lysophospholipids are important intermediates in the
synthesis and degradation of membrane phospholipids.
They regulate a variety of biologic processes, including
cell proliferation and tumor cell invasiveness, and are
involved in inflammation (Moolenaar, 1999; Spiegel and
Milstien, 1995). Lysophosphatidylcholine, produced by
the action of phospholipase A2 on phosphatidylcholine,
promotes inflammatory effects including macrophage
activation, increased expression of endothelial cell adhe-
sion molecules and growth factors (Kume et al., 1992;
Kume and Gimbrone, 1994; Yamamoto et al., 1991),
elicitation of vasoconstriction, and inhibition of endothe-
lium relaxation (Murohara et al., 1994; Okatani et al.,
2001), which is why LPLs effects are generally expected
to be deleterious. Because LPLs levels increase during
cerebral ischemia (Kinouchi et al., 1990; Moto et al.,
1991), a deleterious role of LPLs would be expected in
this pathology. This study suggests that instead of pro-
voking neurotoxicity and neurodegeneration, LPLs, par-
ticularly LPC and LPI, protect vulnerable brain regions
against global ischemic injury. Lysophosphatidylcholine
and LPI are neuroprotective when they are injected in
one single intravenous dose 30 minutes before the onset
of ischemia or 30 minutes after the end of ischemia.
Lysophospholipids also induce a sustained brain toler-
ance, which manifests itself several days after LPL in-
jection. A pretreatment with LPC or LPI (200 nmol/kg)
intravenously injected 1 to 3 days before severe 6-minute
ischemia triggers 98% of cell survival in the CA1 pyra-
midal layer.
A neuronal protection has been also observed in an in
vitro model of excitotoxicity using glutamate treatment.
The level of protection is dependent on the concentration
of glutamate and time of application of the glutamate
treatment. At a concentration of 40-mol/L glutamate,
which causes rapid cell swelling, LPC and LPI (10
mol/L) were both efficient if applied before, during,
and after exposure to glutamate, whereas they had no
effect when applied only during and after the toxic insult.
However, when LPC and LPI (10 mol/L) were applied
only during and after exposure to glutamate, a strong
neuroprotection was obtained at a concentration of 20-
mol/L glutamate, corresponding to the extracellular
glutamate concentration observed in ischemic brains.
FIG. 7. Lysophospholipids induce ischemic tolerance against
transient global forebrain ischemia. This figure represents the
quantitative analysis of CA1 and CA3 cell survival obtained with
lysophosphatidylcholine (LPC) and lysophosphatidylinositol (LPI)
injected at different times (6, 24, 48, 72 and 96 hours) before
6-minute ischemia. Histograms represent the neuronal density
assessed in cresyl violet-stained sections per 1-mm linear length
of hippocampal CA1 and CA3 pyramidal layers in the different
experimental groups submitted to 6-minute global ischemia. Data
represent the mean values ± SEM from counts of two brain sec-
tions per slide and 10 slides per rat (n = 5 per group). Both LPI
and LPC were intravenously injected at a dose of 200 nmol/kg.
LPC corresponds to LPC (C14:0). Sham corresponds to sham-
operated rats injected with vehicle and vehicle to ischemic rats
injected with vehicle 72 hours before the onset of 6-minute isch-
emia. Differences were considered statistically significant when P
< 0.05 (Tukey test). *Significantly different from ischemic ani-
mals, #significantly different from sham-operated animals.
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The differences observed in neuronal protection with
LPL posttreatment between in vivo and in vitro models
give the limits of excitotoxicity models on cell culture. It
is well established that, in vivo, glutamate itself is only
minimally effective as an excitotoxin when it is directly
applied to the brain because both neurons and astrocytes
have active glutamate transport systems that are capable
of taking up glutamate from the extracellular fluid. These
transport systems are not present in the in vitro model
used. With regard to transient ischemia, glutamate re-
leased into the extracellular space is rapidly cleared dur-
ing reperfusion, and the extracellular glutamate increases
are significant but moderate (Obrenovitch and Urenjak,
1997). With 15-minute ischemia, the limit of protection
induced by LPL after treatment is not reached as it is
with an in vitro application of 40-mol/L glutamate.
Longer periods of ischemia are necessary to lose the
protection by LPLs.
The molecular target involved in the neuroprotective
effects of LPLs remains to be unambiguously identified.
However the best candidates we have at hand are the
recently cloned TREK-1, TREK-2, and TRAAK chan-
nels, which correspond to a new class of background K+
channels with a 2P-domain structure (Lesage and Laz-
dunski, 2000; Patel and Honore, 2001; Patel et al., 2001),
and which are strongly activated by certain LPLs
(Lesage et al., 2000; Maingret et al., 2000b). The first
reason to consider these channels as potential targets is
that there is growing evidence that the activation of K+
channels represents an opportunity for a new neuropro-
tective strategy against cerebral diseases. Thus, openers
of ATP-sensitive K+ channels (KATP) have been de-
scribed as potent neuroprotectors against ischemia and
epilepsy (Abele and Miller, 1990; Heurteaux et al., 1993;
Lauritzen et al., 1997; Plamondon et al., 1999), and the
same channel type is clearly involved in ischemic and
epileptic tolerance (Plamondon et al., 1999; Reshef et al.,
1998). The second reason is that PUFAs, which are
known to activate background channels such as TREK1,
TREK2, and TRAAK channels (Fink et al., 1998; Lesage
FIG. 8. Lysophospholipids (LPLs) induce ischemic tolerance against transient global forebrain ischemia. (A) Effects of lysophosphati-
dylcholine (LPC) and lysophosphatidylinositol (LPI) injected at different times (6, 24, 48, 72 and 96 hours) before ischemia on morphologic
changes at the CA1 pyramidal cell layer assessed using cresyl violet staining in rats killed 7 days following ischemia. All LPLs were
intravenously injected at a dose of 200 nmol/kg 30 minutes before 6-minute global ischemia. LPC200 corresponds to LPC (C14:0)
administration at a dose of 200 nmol/kg. Vehicle 3 days Isch6 corresponds to rats intravenously injected with vehicle 72 hours before the
onset of 6-minute global ischemia. Scale bar = 100 µm. (B) Western blot analysis of the temporal induction profile of heat-shock protein
70 (HSP70) in hippocampal extracts following LPI treatment (200 nmol/kg). (C) Histograms correspond to the quantification of HSP70
obtained in Western blotting of hippocampal extracts isolated from vehicle-injected rats (VEH) or rats injected with LPI (200 nmol/kg) and
killed at 6, 24, 48, 72, or 96 hours following injection. The specific bands were quantified by densitometry using an imaging system. Values
are expressed as a percentage of control. Data represent the mean values ± SEM from three separate experiments in each group (n =
3). * P < 0.05 compared with vehicle-injected rats.
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et al., 2000; Patel et al., 1998), prevent neurodegenera-
tion induced by cerebral ischemia or epilepsy (Lauritzen
et al., 2000) and also induce brain tolerance (Blondeau et
al., 2001). Other drugs such as riluzole also activate these
channels and are neuroprotective (Duprat et al., 2000;
Ettaiche et al., 1999; Lang-Lazdunski et al., 1999; Pratt
et al., 1992). The third factor suggesting an important
role of background 2P-domain K+ channels in neuropro-
tection is the parallel obtained between levels of cell
survival and levels of activation of TREK and TRAAK
channels by different LPLs. The LPLs with large polar
heads and long acyl chains, such as LPC and LPI, which
are known to open background channels, prevent neuro-
nal death induced by ischemia and glutamate treatment.
Conversely, no neuroprotection was obtained with
LPA, which is ineffective as an activator of these chan-
nels. In fact, LPA has been reported to induce stimula-
tion of neurite retraction, stimulate astrocyte prolifera-
tion (Jalink et al., 1993; Keller et al., 1997; Tigyi and
Miledi, 1992), and inhibit glutamate uptake by astrocytes
(Keller et al., 1996). Furthermore, high concentrations or
prolonged exposures to LPA induce necrosis and apop-
tosis in hippocampal neurons (Holtsberg et al., 1998).
The opening of TREK and TRAAK channels by LPLs is
expected to lead to a synaptic hyperpolarization (prob-
ably via synaptic TRAAK channels (Lauritzen et al.,
2000; Reyes et al., 2000) as well as an hyperpolarization
of dendrites (probably via TREK1 channels, which are
dendritic; Lauritzen et al., 2000), which would reduce
glutamate release and decrease NMDA receptor-
associated Ca2+-permeable channel activity via a rein-
forcement of Mg2+ blockade. This study showing the
analysis of 1-palmitoyl-LPC transport across the blood–
brain barrier provides an additional argument in favor of
the activation of TREK and TRAAK channels by LPLs
in the neuroprotection observed. When 200-nmol/kg
LPC was intravenously injected, 0.1% entered into the
brain in the form of 55% unmetabolized LPC, leading to
a cerebral LPC concentration in the range known to ac-
tivate TREK and TRAAK channels (Maingret et al.
(2000b). The neuroprotection by LPC and LPI might be
due, in addition to their effect on TREK and TRAAK
channels, to a direct blockade of NMDA channels by
LPLs, which also takes place (Casado and Ascher, 1998).
Lysophospholipids are also known as potent chelators
and contain chaperonelike activities (Kern et al., 2001).
These effects could contribute to the neuroprotective ef-
fects of LPLs, particularly at high concentrations.
Further work is clearly needed to understand the mo-
lecular mechanisms involved in the neuroprotection in-
duced by LPLs, and particularly to demonstrate in a de-
finitive way the role of TREK and TRAAK background
channels. The dominant effect of the activation of TREK
and TRAAK channels in LPL-mediated cell survival
would be proven if specific blockers of these channels
were available, but it is currently unknown whether these
channel blockers exist. The knockout strategy is another
route. Nevertheless, whatever the exact mechanism of
action, the observation that a single intravenous injection
of LPLs exerts strong neuroprotective effects, even when
these compounds are injected after the ischemic insult, is
extremely promising and warrants further clinical inves-
tigation. In addition to these observations, we have an
interesting new model of ischemic tolerance. This phar-
macologic “preconditioning” induced by LPLs may also
be a neuroprotective strategy against irreversible brain
damage for individuals who are at risk for stroke.
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FIG. 9. Analysis of 1-[1–14C]-palmitoyl-LPC transport across the
blood–brain barrier. (A) Percent distribution of total lipids ex-
tracted from brain, liver, spleen, and kidney per gram of tissue
after short-time (15-second) tail vein injection into anesthetized
rats of HBSS/BSA medium containing 200-nmol/kg LPC-1-[1–
14C]-palmitoyl. Lipids were fractionated on TLC plates as de-
scribed in Material and Methods. Each bar represents the mean
± SEM for n = 3 animals. The LPC concentration that reached the
brain was calculated using a brain plasma space equal to 14 µl/g,
as previously determined (Bickel et al., 1996). PC, phosphatidyl-
choline; Palm, fatty acid palmitate (B) Representative photomi-
crographs highlighting the effects of posttreatment with 1-palmi-
toyl-LPC on morphologic changes at the CA1 and CA3 pyramidal
cell layers assessed using cresyl violet staining in rats killed 7
days following 15 minutes ischemia. 1-palmitoyl-LPC was intra-
venously injected at a dose of 200 nmol/kg 30 minutes after
15-minute ischemia. Scale bar = 100 µm.
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